ChoA Pharmaceutical Co., Ltd. Overview
ChoA Pharmaceutical is a small, family-controlled Korean consumer-health manufacturer built on pharmacy-channel over-the-counter (OTC) medicines and health functional foods. It was founded in 1988 by Cho Won-ki, a pharmacist who had run a pharmacy for two decades before he acquired Samkang Pharmaceutical. Its identity rests on drinkable ampoule formats: it introduced Korea's first "double-neck" ampoule in 1995 and today makes about 200 medicines and health foods, including some 30 ampoule products such as Hepos/Hepatos (liver), Fematin (anaemia), Joa Viton (memory/endurance) and the Jalkton children's nutrition line. The model favours pharmacist education and direct pharmacy trade over mass advertising, supported by the affiliated Medipharm chain. Exports reach about 23 countries, led by Southeast Asia. Since 2019 the company has posted seven straight years of operating losses. Its equity has eroded close to share capital, and in 2026 it consolidated shares 5:1 to avoid new KOSDAQ "penny stock" delisting rules. By Q2 2026 it was near operating breakeven, helped by exports.
What the company does
ChoA manufactures and sells finished-dose medicines and consumer health products, mainly in Korea. Morningstar's profile lists treatments for diarrhoea, duodenal and gastric ulcer, gastritis, cough and cold, plus nutrition products, health drinks and mixed drinks for children. The company says its range covers general and specialised medicines, health supplements and pet products, aimed at children, women and the elderly (company profile via Datanyze).
Its core technical competence is liquid oral dosage in single-dose ampoules. The company states it produces about 200 medicines and health foods, including about 30 drinkable ampoule products such as Hepos, Fematin, Vasoclean and Mabis (company "About CHO-A" page). In 2022 it developed and patented a polypropylene ampoule, "CHO-A Safeasy". Patents were filed in 12 overseas jurisdictions, with commercial production from May 2023 (Hankyung, Aug 2022; company history).
Business and revenue model
| Revenue component | Description | Evidence |
|---|---|---|
| Own-manufactured products (제품) | OTC medicines, health functional foods, children's drinks and ampoule products made at Haman | 81% of revenue in Q2 2026 (Butler, from DART) |
| Merchandise (상품) | In-licensed or purchased-for-resale products, e.g. Liposome Vitamin C 1000, sold under exclusive Korean distribution from Cure Support (Netherlands) | 19% of revenue in Q2 2026 (Butler); Dealsite, 4 Aug 2026 |
| Product exports | Own products shipped to about 23 countries | 15.5% of H1 2026 revenue (DailyPharm, 14 Sep 2026) |
| Contract manufacturing (CMO/OEM) | Third-party manufacturing, especially ampoules | Named as one of four 2026 core strategies (DailyPharm, Feb 2026); revenue not separately disclosed |
| E-commerce / home-shopping | Health functional foods sold through partners on TV home-shopping and online | Medigate/Hankyung, Aug 2022; "e-commerce channel diversification" is a 2026 strategy |
| Animal health | Animal medicines and supplements; business purpose added at the March 2024 AGM; launched 2025 | Dealsite, Mar 2024 / Apr 2025; Kormedi, Feb 2026 |
The revenue model is entirely product sales. There is no subscription or recurring licensing revenue.
Value-chain position and customers
ChoA sits in finished-dose formulation, manufacturing and branded distribution. It buys active pharmaceutical ingredients (APIs) and excipients externally; the 2024–25 Galeo stock-out was traced to a process problem with a European API supplier (DailyPharm, Mar 2025). Domestic customers are mainly community pharmacies, served through direct trade. The company says it holds to direct dealing for OTC items, and has ties with Medipharm, a chain of about 1,000 pharmacies (DailyPharm, 2017). Some prescription (ETC) items are made by contract manufacturers and sold through wholesalers (DailyPharm, 2017). Overseas customers are distributors and importers in Southeast Asia, China, the US, Central Asia, Latin America and Africa.
One aggregator (Bullstory) describes a high share of hospital injectables and prescription drugs. Company statements and trade press consistently describe an OTC-centred model, and the company itself said in 2011 that it had no prescription drugs. Bullstory's characterisation is treated as inaccurate.
Company's own description
In its FAQ the company says it wants people everywhere to receive quality treatment regardless of status or location. Its mission is to deliver good-quality drugs at a fair price, working with reliable manufacturers, distributors and wholesalers, under the motto "Keep people happy and healthy, far away from diseases." It also states that all its facilities are located in South Korea. In explaining what sets it apart, it cites an indirect marketing approach that educates pharmacists and doctors rather than relying on mass advertising (company FAQ).
Independent characterisation
ChoA is a micro-cap, legacy pharmacy-OTC house. Its brands are well known (sports sponsorship, notably the long-running CHO-A Pharm Professional Baseball Award), but none of its products has reached the KRW 10 bn "leading OTC" scale. In 2017 management itself said it lacked a KRW 10 bn+ product (DailyPharm, 2017).
Its cost structure is poorly matched to its revenue base. SG&A was about 49% of revenue in 2024, and cost of sales plus SG&A exceeded revenue by 15% (Dealsite, Apr 2025). The many-products, small-batch manufacturing model is exposed to raw-material inflation, generic competition and Korean drug-price cuts. Management named these factors in explaining its 2025 results (Kormedi, Feb 2026).
The 2026 turnaround rests on three things: export growth (Southeast Asia, Latin America, Africa), deep SG&A cuts, and capital-markets measures to stay listed. It is real but early, and the improvement is two quarters old.
Strategy
Stated strategy
January 2026 New Year address (Vice Chairman Cho Sung-hwan): Restructuring is the top priority, pursued through four core strategies: (1) stronger pharmacist partnerships, (2) export expansion, (3) upgrading the CMO business, and (4) diversifying e-commerce channels (DailyPharm, Feb 2026). He also said growth would come from developing good medicines and opening new markets, with 2026 meant as the starting point of a real rebound (Kormedi, Feb 2026).
2026 roadmap (set early 2026): Fostering new businesses, diversifying distribution channels, raising brand value, strengthening digital marketing, and focusing H2 2026 on corporate value enhancement (SBS Biz; Hankyung, Jul 2026).
FY2023 annual report plan: Revive domestic sales, adjust cost ratios, pursue overseas business aggressively and develop new revenue sources (DailyPharm, Mar 2024).
Initiatives announced in the last 24 months
| Initiative | Timing | Detail / targets | Status | Source |
|---|---|---|---|---|
| Animal health entry | Purpose added Mar 2024; launch 2025 | Animal medicines, feed and pet supplies; trademarks registered | Launched; growth described as slow | Dealsite; Kormedi (Feb 2026) |
| Newhem iron-syrup export programme | 2026–2027 | KRW 2.2 bn across 6 countries in 2026; KRW 2.5 bn across 7 countries in 2027 (from KRW 0.7 bn across 4 in 2023) | In progress | SBS Biz; Hankyung |
| Latin America and Africa expansion | Mar 2026 onward | Guatemala (Hepatos, Elas-A); DR Congo | In progress | DailyPharm; SBS Biz |
| Cost restructuring | 2,026 | H1 SG&A -12.8%; salaries -13.2%; advertising -70.7% | Delivered in H1 | DailyPharm (Sep 2026) |
| 5:1 share consolidation | Announced Jun 2026; approved 6 Jul 2026; effective 27 Aug 2026 | Lift the share price above KRW 1,000; the company also cites a suitable share float and price stability | Completed | SBS Biz; Daum/Newsis; DailyPharm |
| In-licensed premium supplements | Jul 2026 | Exclusive Korean sale of Liposome Vitamin C 1000 | Launched; strong first week | Dealsite (Aug 2026) |
| Land revaluation | H1 2026 | About KRW 10.1 bn revaluation surplus added to equity | Booked | DailyPharm (Sep 2026) |
| Wastewater remediation | 2,025 | Facility upgrades and external self-testing; resumption of production | Completed | DailyPharm (Jan 2025); TheVC |
Guidance and medium-term targets
No formal revenue or margin guidance was found for 2026–2027 beyond the Newhem export targets. Historical guidance has been unreliable: in 2022 the company targeted KRW 70 bn revenue and an operating profit, and delivered KRW 68.9 bn revenue with an operating loss of KRW 0.5 bn (Hankyung, Aug 2022). In 2017 it targeted KRW 60 bn revenue (DailyPharm, 2017). No ESG or sustainability targets are publicly disclosed.
Products & Services
ChoA's catalogue runs to about 200 SKUs. The items below are those individually documented in public sources. Pricing is not publicly disclosed for any item.
OTC medicines (pharmacy channel)
| Product | Category / description | Target customer | Launch / status | Key facts | Source |
|---|---|---|---|---|---|
| Joa Viton (조아바이톤) | OTC aimed at memory improvement and endurance | Adults, students, elderly | Long-standing | Sales rose about 65% in 2010 to nearly KRW 6 bn; weaker sales in H1 2024 | eToday (2011); Bizwatch (2024) |
| Fematin (훼마틴) | Haematinic (anaemia) ampoule | Women, pregnant women | Long-standing; flagship ampoule | +24.1% in 2010; weaker in H1 2024 | eToday (2011); company site |
| Hepos Syrup (헤포스시럽) | Ampoule liver drug made under Laphal technical cooperation; 30-ampoule and 4-ampoule packs | Adults | Launched Jul 2007 | Supplied mainly through Medipharm pharmacies at launch | DailyPharm (2007) |
| Hepatos Syrup (헤파토스시럽) | Liver-function agent | Adults (drinking occasions) | Current | Sales up more than 40% QoQ in Q2 2022; exported to Guatemala from Mar 2026 | Hankyung/Medigate (2022); DailyPharm (2026) |
| Galeo (가레오) liquid and soft capsules | DHBE (dihydroxydibutylether), a choleretic/digestive agent | Adults with dyspepsia | Approved 1999 | Sales KRW 2.4 bn (2020), 1.6–1.8 bn (2021–23) and 0.48 bn (2024) during a stock-out that began mid-2024; MFDS clinical re-evaluation narrows the dose to 0.5 g three times a day | DailyPharm (Mar 2025; Sep 2024) |
| Uranitin solution (우라니틴액) | L-ornithine-L-aspartate single-ingredient liquid (20 mL × 20 ampoules) | Adults (hangover, fatty liver) | Jul 2007 | Described at launch as the only domestically produced LOLA single-ingredient liquid | DailyPharm (2007) |
| Elas-A solution (엘라스에이액) | OTC liquid | Adults | Current | Exported to Guatemala from Mar 2026 | DailyPharm (Sep 2026) |
| Newhem Syrup / Newhem Forte Syrup (뉴헴시럽 / 뉴헴포르테시럽) | Iron supplements for iron-deficiency anaemia | Emerging markets: Africa and Southeast Asia | Current | Exports about KRW 0.7 bn across 4 countries (2023); target KRW 2.2 bn across 6 countries (2026) and KRW 2.5 bn across 7 (2027) | SBS Biz; Hankyung (Jul 2026) |
| Naspen Syrup (나스펜시럽) | Squeeze-pack children's fever and pain reliever | Children | Recent | Listed in DailyPharm related coverage | DailyPharm |
| Choeun-i (조은아이) | OTC (eye health per brand naming) | Adults | Current | Named among key brands | DailyPharm (Mar 2024) |
| Vasoclean, Mabis | Drinkable ampoule products | Adults | Current | Named by the company among its 30 ampoule products | Company "About" page |
| Others (company list, older translation) | Vita Crayon Plus chewable tablets, nasal liquid, Eleanor Men's syrup and others | Various | Various | Machine-translated company list; names partly garbled | HealthManagement.org listing |
Children's nutrition and health functional foods
| Product | Description | Market | Launch | Key facts | Source |
|---|---|---|---|---|---|
| Jalkton (잘크톤) family | Children's nutrition and health drink line | Korea | About 2006 (20th anniversary in 2026) | Cumulative sales above 10.45 million units by end-June 2026; +16% in Q2 2022; weaker in H1 2024 | Hankyung (Jul 2026); Medigate (2022) |
| Jalkton step1 | Children's nutrition supplement | Indonesia | Feb 2021 | Export line extension | Company history |
| Jalkton Dino Kids | Children's nutrition supplement | Uzbekistan | Aug 2025 | Central Asia entry | Company history |
| Smart Dino / Long Dino | Children's drinks | Vietnam | Aug 2016 | Vietnam-specific lines | Company history |
| Licensed-character children's drink | Children's drink using a licensed cartoon franchise | Korea | Announced 2022 | — | Hankyung (Aug 2022) |
| Liposome Vitamin C 1000 | Liposomal vitamin C, 1,000 mg per sachet; exclusive Korean distribution of a Cure Support (Netherlands) product | Adults | Late Jul 2026 | 8,000 boxes (240,000 sachets) sold in the first week | Dealsite (4 Aug 2026) |
| Home-shopping/online health foods | 3–4 products prepared for home shopping in H2 2022, targeting about KRW 5 bn | Korea | 2,022 | Partner-led distribution | Hankyung (Aug 2022) |
| Dunggule 9水 | Solomon's-seal tea beverage | Korea | May 2007 | Early diversification into beverages | eToday (2007) |
Platforms, services and new businesses
| Offering | Description | Status | Source |
|---|---|---|---|
| CHO-A Safeasy Ampoule | Polypropylene single-dose ampoule developed over about four years. The company says it releases no environmental hormones. Patented in Korea, with filings in 12 countries including the US, EU, Japan and China. | Commercial production from May 2023; positioned for own products and OEM | Hankyung (Aug 2022); company history |
| Contract manufacturing (CMO) | Formulation-to-manufacture services; the company cites expertise from early formulation to GMP scale-up and distribution | 2026 strategic priority ("CMO upgrade") | Company FAQ; DailyPharm (Feb 2026) |
| Animal health | Animal medicines and supplements; trademarks registered | Launched 2025; product brand and sales not publicly disclosed | Dealsite; Kormedi |
| Masks (OEM) | COVID-era masks via OEM, not own production | 2,020 | Dealsite (Feb 2020) |
Financial Narrative
Income statement
Sources: revenue, operating income, net income and operating cash flow from OpenDART (consolidated) via Bullstory and Butler. SG&A, personnel, advertising and the cost ratio are from Dealsite (Apr 2025). FY2024 gross profit is derived here: 115.4% × 62.7 = KRW 72.4 bn total costs, less KRW 30.8 bn SG&A, gives about 41.6 bn COGS and about 21.1 bn gross profit. FY2023 advertising is derived from the stated +149.7% increase to KRW 2.3 bn.
Margins and growth
All margins are calculated here from the figures in 6.1; FY2024 gross margin is derived. Bullstory independently reports net margins of -14.0%, 0.7%, -17.7%, -16.2% and -12.4%, consistent within rounding.
Revenue CAGR: FY2021–FY2025 about +0.7% a year. From the FY2022 peak to FY2025 about -4.9% a year. Both calculated here.
Interim trend
Sources: The Fact (May 2024); Bizwatch (Aug 2024); DailyPharm (Nov 2025; 14 Sep 2026). Q1 2025 and Q1 2026 revenue and net income are derived as H1 less Q2. Q1 2026 operating loss of KRW 1.12 bn is as reported by DailyPharm; unips cites Q1 2026 revenue of about KRW 14.7 bn, consistent with the derivation.
H1 2026 cost detail (DailyPharm). Gross profit rose 6.7%. SG&A fell 12.8%, with salaries down 13.2% (KRW 6.4 bn to 5.6 bn) and advertising down 70.7% (KRW 1.0 bn to 0.3 bn). Gross margin was stable at about 36.7%, calculated here. The swing to profit came almost entirely from opex.
Balance sheet
Sources: Kormedi KRX notice (FY2025 assets, liabilities, equity); DailyPharm (Nov 2025; Sep 2026); Dealsite (Apr 2025). Equity of KRW 28.5 bn per Dealsite versus 28.6 bn per DailyPharm is a rounding difference. Share capital is assumed constant at about KRW 15.5 bn; pre-2023 values are not separately verified. The ratio row is calculated here.
Interim data points.
Q3 2025: equity KRW 24.4 bn; accumulated deficit KRW 51.6 bn (DailyPharm, Nov 2025).
30 Jun 2026: equity KRW 32.1 bn, including about KRW 10.1 bn of land revaluation surplus. Total borrowings KRW 24.54 bn. Inventory KRW 10.85 bn. The "capital procurement ratio" (borrowings relative to total capital) fell from 51.0% to 40.9% (DailyPharm, 14 Sep 2026).
End-2023: cash about KRW 1.9 bn (Dealsite headline, Mar 2024).
Net debt. About KRW 23 bn at end-2025 if cash was on the order of KRW 2 bn.
Cash flow
Source: OpenDART via Bullstory. No dividends since 2001 (DailyPharm, Dec 2025). No buyback programme was found in the period reviewed.
Ratios
Calculations by the analyst. FY2024 ROE uses average equity of (38.8 + 28.5) / 2. Stockhub reports a TTM ROE of -28.64%, consistent. Current ratio, ROIC, interest coverage, net debt/EBITDA, asset turnover and the cash conversion cycle cannot be computed reliably from verified data and are not publicly disclosed in the sources reviewed. Interest coverage is negative: operating income has been below zero every year since 2019.
Commentary on trends, inflections and drivers
Revenue. Revenue peaked at KRW 68.9 bn in 2022, a COVID-reopening rebound. The company tied that year's demand to the end of social-distancing rules: Hepatos rose with the return of social drinking and Jalkton with heightened health concern. Revenue then fell to KRW 59.3 bn in 2025, roughly back to 2018 levels (KRW 63.1 bn in 2018). Management cites lower domestic sales, weaker overseas sales in 2023, rising raw-material costs, generic competition and drug-price cuts (DailyPharm, Mar 2024; Kormedi, Feb 2026). Two specific shocks hit 2024–25: the Galeo stock-out, which cut a KRW 1.6–2.4 bn product to KRW 0.48 bn, and the Haman wastewater shutdown from 24 Jan 2025.
Profitability. Operating losses have run for seven consecutive years (2019–2025). The cumulative operating loss is about KRW 32.7 bn (Kormedi). Cost of sales plus SG&A rose from 100.7% of revenue in 2022 to 115.4% in 2024. Personnel costs were about half of SG&A, and advertising more than doubled in 2024 (Dealsite).
Inflection. The 2026 inflection comes from cost cuts rather than gross-margin expansion. Gross margin was flat; SG&A fell 12.8%. Q2 2026 operating loss was only KRW 23 million, and H1 2026 net income was KRW 0.23 bn, versus a KRW 3.78 bn loss in H1 2025.
Balance sheet. Equity fell from KRW 38.8 bn (2023) to 21.8 bn (2025), only about 1.4 times share capital. That raised the prospect of partial capital impairment (부분자본잠식) within one to two years at 2024 loss rates (Dealsite, Apr 2025). The mid-2026 land revaluation, adding about KRW 10.1 bn to equity, is non-cash and does not reflect operating improvement. DailyPharm explicitly cautions that it does not represent earnings-driven repair.
Cash. Operating cash flow has been negative every year from 2021 to 2025, so the business has been funded by borrowings, which stood at about KRW 25 bn.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Stake | Activity | Source |
|---|---|---|---|---|
ChoA Pharmaceutical Co., Ltd. | Listed parent | — | OTC/health-food manufacturing and sales | — |
Medipharm (메디팜) | Affiliate/subsidiary | 49.06% | Pharmacy franchise and drug sales; about 1,000 chain pharmacies (2017) | Dealsite; DailyPharm (2017) |
IB Smart (아이비스마트) | Subsidiary | 93.81% | Sports facility operation. ChoA bought 33,334 more shares for KRW 0.4 bn in early 2024. | Dealsite; Bizwatch (Aug 2024) |
Vietnam subsidiary | Subsidiary | 100% | Market presence in Vietnam (HCMC office since 2016) | Dealsite; company history |
Panbiotech (팬바이오텍) | Former investee | Exited May 2024 | Biotech affiliate; investment recovered | Bizwatch (Aug 2024) |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue (KRW Bn) | 57.6 | 68.9 | 63.0 | 62.7 | 59.3 |
Product exports (KRW Bn) | — | — | — | 6.831 | 5.840 |
Revenue excluding product exports (KRW Bn, derived) | — | — | — | 55.869 | 53.460 |
Product exports share of revenue (%, derived) | — | — | — | 10.9 | 9.8 |
Revenue by Segment
| Metric (half-year) | H1 2023 | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Domestic revenue (KRW Bn) | 22.1 | 20.1 | — | — |
Product exports (KRW Bn) | — | — | 2.606 | 4.641 |
Product revenue, own-manufactured (KRW Bn) | — | — | 22.06 | 24.00 |
Total revenue (KRW Bn) | 32.4 | 30.5 | 28.015 | 29.866 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 57.6 | 68.9 | 63.0 | 62.7 | 59.3 |
Revenue growth YoY (%) | — | 19.6 | -8.6 | -0.5 | -5.4 |
Gross profit (KRW Bn) | — | — | — | 21.1 | — |
Operating income (KRW Bn) | -7.0 | -0.5 | -6.8 | -9.6 | -6.6 |
Net income (KRW Bn) | -8.0 | 0.5 | -11.1 | -10.2 | -7.4 |
Operating cash flow (KRW Bn) | -1.5 | -1.4 | -1.5 | -4.5 | -4.2 |
SG&A (KRW Bn) | — | — | — | 30.8 | — |
Personnel cost in SG&A (KRW Bn) | — | — | — | 15.3 | — |
Advertising expense (KRW Bn) | — | — | 0.92 | 2.3 | — |
Cost of sales plus SG&A as % of revenue | — | 100.7 | 110.9 | 115.4 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | 33.6 | — |
Operating margin (%) | -12.2 | -0.7 | -10.8 | -15.3 | -11.1 |
Net margin (%) | -13.9 | 0.7 | -17.6 | -16.3 | -12.5 |
SG&A as % of revenue | — | — | — | 49.2 | — |
OCF as % of revenue | -2.6 | -2.0 | -2.4 | -7.2 | -7.1 |
Income Statement
| Metric | Q1 2024 | H1 2024 | Q1 2025 | Q2 2025 | H1 2025 | 9M 2025 | Q1 2026 | Q2 2026 | H1 2026 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 14.7 | 30.5 | 14.375 | 13.640 | 28.015 | — | 14.684 | 15.182 | 29.866 |
Operating income (KRW Bn) | -1.4 | -3.5 | -2.106 | -1.503 | -3.609 | -5.1 | -1.120 | -0.023 | -1.143 |
Net income (KRW Bn) | -1.37 | -3.2 | — | — | -3.781 | — | -0.150 | 0.377 | 0.227 |
Gross profit (KRW Bn) | — | — | — | — | 10.282 | — | — | — | 10.973 |
SG&A (KRW Bn) | — | — | — | — | 13.891 | — | — | — | 12.116 |
Balance Sheet and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | — | — | — | — | 64.7 |
Total liabilities (KRW Bn) | — | — | — | — | 42.9 |
Total equity (KRW Bn) | — | — | 38.8 | 28.5 | 21.8 |
Share capital (KRW Bn) | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 |
Accumulated deficit (KRW Bn) | — | — | 38.2 | 47.8 | — |
Total borrowings (KRW Bn) | — | — | — | — | 24.98 |
Inventory (KRW Bn) | — | — | — | — | 11.72 |
Equity-to-share-capital ratio (x) | — | — | 2.50 | 1.84 | 1.41 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | -1.5 | -1.4 | -1.5 | -4.5 | -4.2 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
ROE (%, average equity) | -30.4 | -29.4 |
ROA (%, period-end assets) | — | -11.4 |
Liabilities to equity (%) | — | 196.8 |
Borrowings to equity (x) | — | 1.15 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Product exports (KRW Bn) | — | 6.831 | 5.840 |
Product exports YoY growth (%) | — | — | -14.5 |
Newhem series exports (KRW Bn) | 0.7 | — | — |
Revenue by Region and Revenue by Region (%)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Product exports (KRW Bn) | 2.606 | 4.641 |
Product exports share of revenue (%) | 9.3 | 15.5 |
Country / Region Details
| Country / region | Products | Date | Source |
|---|---|---|---|
Vietnam | Ampoules (since 1995); Smart Dino and Long Dino (2016); HCMC office (2016) | 1995 onward | Company history |
Indonesia | Jalkton step1 | Feb 2021 | Company history |
Uzbekistan | Jalkton Dino Kids | Aug 2025 | Company history |
Guatemala | Hepatos Syrup, Elas-A solution | Mar 2026 | DailyPharm (Sep 2026) |
DR Congo | Export network extension (Newhem iron syrups targeted at Africa) | 2026 | SBS Biz; Hankyung (Jul 2026) |
Myanmar, Cambodia, China, US | Various | Ongoing | DailyPharm (Sep 2026) |
Middle East | Exhibited at Arab Health Dubai | Feb 2020 | Company history |
Japan | Exhibited at ifia / HFE Japan | May 2025 | Company history |
Share Price History
| Date | Price (KRW) | Market cap (KRW Bn) | Source |
|---|---|---|---|
26 Aug 2020 | Peak period | 205.7 | DailyPharm (Mar 2024) |
2019 (gift date) | 3,700 | — | Dealsite (Apr 2025) |
Early Feb 2020 | 4,100 (after a spike to about 5,000) | — | Dealsite (Feb 2020) |
Mar 2024 | — | About 50 (KRW 50–60 bn range) | DailyPharm (Mar 2024) |
1 Apr 2025 | 995 (52-week high 1,833) | — | Dealsite (Apr 2025) |
28 Nov 2025 | 997 | 30.9 | DailyPharm (Dec 2025) |
19 Feb 2026 | 1,011 | 31.3 | DailyPharm (Feb 2026) |
20 Feb 2026 | 997 | 30.9 | Kormedi |
Jun 2026 | About 1,000 range, with limit-up spikes | 30+ | DailyPharm (Jun 2026) |
~8 Jul 2026 | 568 (52-week range 498–1,420) | 17.6 | Stockhub |
23 Jul 2026 | 606 | — | Bullstory |
31 Jul 2026 | 585 (last pre-halt close) | About 18.1 | Kormedi; Bullstory |
Valuation Multiples
| Multiple | ChoA | Basis / source |
|---|---|---|
P/E | Not meaningful (loss-making on a trailing basis) | Stockhub; Butler |
P/B | 0.48 (Butler, date not stated); 0.77 (Stockhub, July 2026) | Aggregators |
EV/Sales | About 0.7x (estimate) | — |
EV/EBITDA | Not meaningful (EBITDA not disclosed; operating income negative) | — |
Capital Markets
| Item | Status | Source |
|---|---|---|
Analyst coverage and consensus | None (0 reports) | Stockhub |
Dividend history | None since 2001; dividend yield not applicable | DailyPharm (Dec 2025); Butler |
Buyback authorisation | None found; treasury share ratio not shown | Butler |
Credit ratings (Moody's, S&P, Fitch) | Not rated | — |
Debt maturity profile | Not publicly disclosed; total borrowings KRW 24.54 bn at 30 Jun 2026 | DailyPharm (Sep 2026) |
Listing thresholds | Market cap of KRW 20 bn now (about KRW 3,228 per share on 6.2 million shares); KRW 30 bn from Jul 2027 (about KRW 4,842) | DailyPharm (Sep 2026) |
Analyst Conclusions
Management guidance and consensus
There is no formal guidance and no analyst consensus. Management's stated aims are:
-
delivering tangible operating results in H2 2026 to lift corporate and shareholder value (SBS Biz, Jul 2026);
-
Newhem exports of KRW 2.2 bn in 2026 and KRW 2.5 bn in 2027;
-
continued export growth to new countries.
On H1 trends, DailyPharm observes that FY2026 product exports could exceed both the 2025 total (KRW 5.84 bn) and the 2024 total (KRW 6.83 bn).
Bull case
-
Operating breakeven is in sight. The Q2 2026 operating loss was only KRW 23 million on revenue of KRW 15.18 bn (+11.3%). Holding H1 2026's SG&A run-rate of about KRW 24 bn a year, against about KRW 30.8 bn in 2024, with a gross margin near 36.7%, implies breakeven at roughly KRW 66 bn of revenue, or lower with mix gains (estimate). Export momentum makes FY2027 profitability plausible.
-
Exports are a real growth engine. H1 2026 product exports rose 78.1% and the export share reached 15.5%. Latin America, Africa and Central Asia registrations, together with emerging-market iron demand, extend a 30-year Southeast Asian franchise.
-
Deep asset discount. At a P/B of about 0.5–0.8, on equity of KRW 32.1 bn after revaluation, and with no analyst coverage, a return to profit could re-rate the stock sharply. The consolidation removed the penny-stock overhang.
Bear case
-
The balance sheet is fragile and the repair is cosmetic. About KRW 10.1 bn of the H1 2026 equity increase is land revaluation. Operating cash flow was negative from 2021 to 2025 and borrowings are about KRW 25 bn. A rights issue, which would dilute existing holders, remains a live possibility (DailyPharm, Nov 2025).
-
The core domestic franchise keeps shrinking. Domestic product sales are falling (DailyPharm, Jun 2026). Flagship brands weakened in 2024, and Galeo lost about 70% of its sales. Cost cutting, including a 70% cut in advertising, may accelerate brand erosion.
-
Listing risk is postponed, not removed. The share price must reach about 5.5 times the pre-consolidation-equivalent level to clear the KRW 20 bn market-cap threshold, and more to clear KRW 30 bn from July 2027. One more operational shock (environmental, API supply or price cuts) could reverse the progress, given single-plant concentration.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q3 2026 quarterly report | By mid-Nov 2026 | First quarterly operating profit? Export run-rate; SG&A discipline |
| FY2026 preliminary and annual results | Feb–Mar 2027 | End of the seven-year operating-loss streak; operating cash flow sign |
| Market cap against the KRW 20 bn and KRW 30 bn thresholds | Continuous; KRW 30 bn rule from Jul 2027 | Price above about KRW 3,228 and KRW 4,842 on the consolidated basis |
| Newhem export delivery | FY2026 | Against the KRW 2.2 bn and six-country target |
| Capital raising | Any time | Rights issue, CB issue or asset sales |
| Galeo re-evaluation outcome and supply | 2026–2027 | Product continuation or withdrawal |
| Succession and share transfers | Any time | Gifts from the founder (born 1940) to his sons |
| Environmental compliance at Haman | Ongoing | Any repeat violation |
| Animal health and CMO revenue disclosure | FY2026 annual report | Evidence the new businesses have scale |
Analyst verdict
ChoA Pharmaceutical is a turnaround candidate with a credible first leg and an unproven second. On the evidence of the H1 2026 report, management has stopped the bleeding where it was most controllable. SG&A fell by about KRW 1.8 bn in six months, and product exports nearly doubled, taking the Q2 operating loss to a rounding error and producing a half-year net profit for the first time since 2022. These are concrete improvements, not narrative. Yet they rest on a narrow base: two quarters of data, a gross margin that has not improved, and an advertising cut that buys margin today at the cost of brand equity tomorrow.
The structural problems remain. Revenue is still below its 2018 level. The Korean pharmacy OTC franchise that defined the company is shrinking. The company has no product of meaningful scale. Its single plant has already shown how quickly one compliance failure can threaten three-quarters of output. The balance sheet was repaired by revaluing land, not by earning money. Operating cash flow was negative in each of the five years to 2025, borrowings are about 1.1 times equity, and a capital raise cannot be ruled out.
The capital-markets overlay is decisive for equity holders. The 5:1 consolidation resolved the penny-stock test, but KOSDAQ's KRW 20 bn market-cap floor, rising to KRW 30 bn in July 2027, is a hard deadline. Only sustained profitability is likely to clear it.
On balance, ChoA is a high-risk, event-driven micro-cap whose investment case hinges almost entirely on converting Q2 2026's breakeven into consistent operating profit and positive operating cash flow by FY2027. The Q3 2026 report is the next decisive data point. Until then, the risk/reward is speculative, with a wide range of outcomes: a re-rating if export-led profitability holds, or dilution or delisting pressure if it does not.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Born | Tenure / background | Source |
|---|---|---|---|---|
Cho Won-ki (조원기) | Founder, Chairman, inside director; largest shareholder | 1,940 | Pharmacist who ran a pharmacy for about 20 years before acquiring Samkang in 1988; CEO until 2004; known for 20+ years of public health-education lectures | The Fact (2024); Dealsite; DailyPharm (2017) |
Cho Sung-hwan (조성환) | Vice Chairman and co-CEO | 1,970 | CEO since 2004; Vice Chairman since 2017; also CEO of Medipharm. Historically led exports and biotech R&D; more recently leads marketing. | Dealsite; eToday (2014); The Fact (May 2024); DailyPharm (Nov 2025) |
Cho Sung-bae (조성배) | President and co-CEO | 1,972 | Former Vice President of Medipharm; co-CEO since Nov 2014; historically led domestic pharmacy sales | eToday (2014); DailyPharm (2017); Dealsite |
Major Shareholders
| Holder | Shares (pre-consolidation, end-2024) | Stake (%) | Source |
|---|---|---|---|
Cho Won-ki | 3,508,843 | 11.3 | Dealsite (Apr 2025) |
Cho Sung-hwan | 1,893,162 | 6.1 | Dealsite (Apr 2025) |
Cho Sung-bae | 794,000 | 2.6 | Dealsite (Apr 2025) |
Family total | 6,196,005 | 20.0 | Calculated here |
Competitive Landscape
Competitors by Segment
| Segment | Competitors (Korea unless noted) | Overlap with ChoA |
|---|---|---|
Pharmacy OTC: liver, digestive and ampoule drinks | Dong-A Pharmaceutical, Kwang Dong Pharmaceutical, Dongwha Pharm, Ildong Pharmaceutical, Daewoong Pharmaceutical, Samjin Pharm | Liver tonics, digestives, drinkable formats |
Haematinics and vitamins | Yuhan Corp, Daewoong (Impactamin), Kyung Nam Pharm, Ildong | Fematin, Newhem, Liposome Vitamin C |
Children's nutrition drinks and supplements | Dong-A, Ildong, Kwang Dong, Boryung Consumer Healthcare | Jalkton family |
Small-cap KOSDAQ consumer pharma under listing pressure | Kyung Nam Pharm (also rallied on 2026 share-price-management news) | Similar investor profile |
Animal health | Yuhan (Willowpet, Zedacure), Dong-A (Vetple), Daewoong (Daewoong Pet), Dongkook (Canidol), Jong Kun Dang Bio (Labivet), Yuyu Pharma, Kwang Dong, GC Cell | Late entrant (2025) into a crowded field |
Contract manufacturing of liquids and ampoules | Domestic liquid-dose contract manufacturers (fragmented) | Safeasy-based OEM |
Competitor Detail
| Metric | ChoA (FY2025) |
|---|---|
Revenue (KRW Bn) | 59.3 |
Revenue growth (%) | -5.4 |
Operating margin (%) | -11.1 |



